

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Habib Zaghouani, et al.  
App. No.: 10/681,788  
Conf. No.: 1644  
Filing Date: October 8, 2003

Title: Sustained Treatment of Type 1 Diabetes After  
Expression of Predisposition Markers  
Art Unit: 1644  
Examiner: Gerald R. Ewoldt

Commissioner for Patents  
PO BOX 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)**

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, and §§ 1.97 - 1.987 as supplemented by MPEP § 609, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and made of record. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application.

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey LLP Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: November 21, 2006

By:



David B. Fournier  
Registration No.: 51,696  
Customer No.: 22930

Enclosures:

Form PTO-SB-08A and SB-08B

Copies of foreign and non-patent literature references

HOWREY LLP  
ATTN: Docketing Department  
2941 Fairview Park Drive, Suite 200  
Falls Church, VA 22042-9922  
Telephone No.: (703) 663-3600  
Facsimile No.: (703) 336-6950